Previous studies have found a strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome in Asian areas including Taiwan, Hongkong and Thailand. This study explores the association between HLA-B*1502 allele and carbamazepine-induced cutaneous adverse reactions in Han Chinese of southern China mainland, and find the genetic marker that can predict carbamazepine-induced cutaneous adverse reactions.
HLA-B*1502 allele genotyping was performed by a polymerase chain reaction-sequence specific primers (PCR-SSP) method in 48 Han Chinese subjects who had carbamazepine-induced cutaneous adverse reactions, including 9 severe cutaneous adverse reaction patients with Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) and 39 cutaneous adverse reaction patients with maculopapular eruption (MPE). Meanwhile 80 carbamazepine-tolerant controls and 62 healthy individuals were also tested.
The frequency of HLA-B*1502 allele among SJS/TEN patients (100%) is significantly higher than carbamazepine-tolerant controls (13.75%, P < 0.001) and healthy individuals (17.74%, P < 0.001). But the frequency between MPE patients and carbamazepine-tolerant controls (25.64% vs.13.75%, P = 0.110) did not have any significant difference.
The data showed that HLA-B*1502 allele is strongly associated with carbamazepine-induced SJS/TEN but not MPE in Han Chinese of southern China mainland.
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had no history of drug induced cutaneous adverse reactions. In healthy individuals group (27 men and 35 women), the mean age were 38.08 AE 13.60. The study was performed in accordance with the Declaration of Helsinki and its amendments and the document of informed consent was obtained from all subjects.
Genotyping
Genomic deoxyribonucleic acid (DNA) was isolated from peripheral blood using the Genomic DNA Isolation Kit (Shanghai Watsonbiot Technology Co., China). HLA-B*1502 genotype was determined by polymerase chain reaction using sequence specific primers (PCR-SSP). 4 Four sets of HLA-specific primers (Pair1:
0 -GCCATACATCCTCTGGATGA -3 0 )and 2 sets of internal control primers (PairC1:
) were used to perform PCR. 4, 9 The amplified fragment length of Pair1 to Pair4 PCR products were 1340 base pairs (bp), 125 bp, 562 bp, 369 bp respectively, while the PairC1 and PairC2 PCR products were 796 bp and 256 bp. The PCR conditions consisted of a denaturation step at 968 C for 60 s; 5 cycles of 968 C for 20 s, 708 C for 45 s, and 728 C for 25 s; 21 cycles of 968 C for 25 s, 658 C for 50 s, 728 C for 30 s; 4 cycles of 968 C for 30 s, 558 C for 60 s, and 728 C for 90 s. Cool by ramping to 208 C for 30 s prior to termination of the program. PCR products were analyzed by electrophoretic separation on 2% agarose gels, followed by direct visualization over an ultraviolet transilluminator after ethidium bromide staining. Presence of all 4 HLA-specific PCR products and 2 internal control PCR products denotes HLA-B*1502.
Statistics
Data were counted by positive or negative for HLA-B*1502. Chisquare test and Fisher's exact test were used to analyze the association between carbamazepine-induced cutaneous adverse reactions and HLA-B*1502. The strength of association was estimated by calculating the odds ratio.
5 P-values 0.05 (twosided) were considered to indicate statistical significance. Positive predictive value, negative predictive value, sensitivity and specificity were analyzed by fixed formula.
Results
Frequency of HLA-B*1502 genotype in three groups was shown in Table 1 . All of the 9 carbamazepine-induced severe cutaneous adverse reaction patients carried HLA-B*1502. It showed significant increase in HLA-B*1502 allele frequency when compared with two control groups, carbamazepine-tolerant group (100% vs. When carbamazepine-tolerant group was used as control, the presence of HLA-B*1502 had a 45% positive predictive value for CBZ-SJS/TEN, whereas its absence had a negative predictive value of 100%. As the test for CBZ-SJS/TEN, HLA-B*1502 allele had 100% sensitivity and 86.25% specificity.
Discussion
In healthy individuals, the frequency of HLA-B*1502 allele observed in our study was 17.74%, which was a little higher than the study in healthy Han Chinese by Li Yan (11.5%). 6 We presumed our small sample make the difference. However the allele frequency of HLA-B*1502 was only 1-2% in prior studies of European populations. 7 The obviously low frequency of HLA-B*1502 in European might explain the reason of rare morbility of SJS/TEN in Caucasian compared with Chinese. Our study explores the association between HLA-B*1502 and carbamazepine-induced cutaneous adverse reaction in Han Chinese living in southern China mainland possessing the most Han Chinese in the world. Although our study obtained a limited number of patients, all of 9 cases with CBZ-SJS/TEN carried HLA-B*1502 allele. The difference of association with HLA-B*1502 allele was markedly significant comparing with the controls. Similar association was reported in other areas. Chung et al. found that HLA-B*1502 allele was present in 100% of 44 CBZ-SJS Han Chinese patients living in Taiwan but in only 3% of CBZtolerant patients and in 9% of the control population. 8 Since HLA-B*1502 was showed strong association with CBZ-SJS/TEN in Taiwan, similar result was also detected in Hongkong. 9 A followup study in Thai people, another Asian population who are nonHan Chinese, got result in coincide with previous study in Taiwan. 10 But the association between HLA-B*1502 and CBZ-SJS/ TEN could not be confirmed in Japanese, 11 HLA-B*1502 was even not detected in any of 486 healthy Japanese. 12 Studies in Caucasians found no association between HLA-B*1502 and CBZ-SJS patients who were European ancestry. 13 Thus, HLA-B*1502 allele did not exist in CBZ-SJS/TEN patients of all ethnicities. We postulated the failure might be explained by differences in linkage disequilibrium patterns between ethnic groups. It prompted that genetic association of HLA-B*1502 and CBZ-SJS/TEN is ethnicity specific. Unlike CBZ-SJS/TEN, we genotyped HLA-B*1502 allele in CBZ-MPE in Han Chinese of southern China mainland, no significant association was found when compared with frequency in the CBZtolerant group or healthy individuals. The finding was in accordance with reports in Taiwan and Hongkong.
9,14 SJS/TEN and MPE might belong to different types of cutaneous adverse reactions, SJS/TEN are characterized by bullous lesion, while MPE is non-bullous reaction. So we considered that genetic association of carbamazepine induced cutaneous adverse reactions is phenotype-specific.
In conclusion, we confirmed the strong association between HLA-B*1502 and CBZ-SJS/TEN in Han Chinese of southern China mainland. On the contrary, no association between HLA-B*1502 and CBZ-MPE was observed. As a test for CBZ-SJS/TEN, it revealed 100% sensitivity, 86.25% specificity, 45% positive predictive value and 100% negative predictive value of HLA-B*1502. Owing to data in our study, we suggested HLA-B*1502 allele as a useful prediction 
